Search for contacts, projects,
courses and publications

Francesco Bertoni


Prof. Francesco Bertoni is the head of the Lymphoma Genomics group at Institute of Onolcogy Research in Bellinzona, Switzerland, the Institute deputy director, and Adjunct Professor at the Università della Svizzera italiana (USI).His research topics are the development of new anti-lymphoma compounds and lymphoma genomics. Bertoni obtained a Medical Degree magna cum laude (1994) and the Medical Oncology Specialty (1998) from the State University of Milan (Italy). During his career he has worked in Milan (Ospedale Maggiore Policlinico and “Mario Negri” Institute of Pharmacological Research), London (Institute of Child Health and The Barts and The London) and in Ticino (Servizio Oncologico Cantonale). Since April 2003, he has been leading his group is in Bellinzona. Since 2019 he is the President of the Local Organizing Committee of the International Conference on Malignant Lymphoma (ICML). Since January 2009 he is the Editor-in-Chief of Hematological Oncology. Bertoni has supervised several Master and PhD students. Bertoni actively participates to Swiss Cancer Research Group (SAKK), in which he is the President of the Project Group Lymphoma and member of the Project Group Developmental Therapeutics. Prof. Bertoni is the author or co-author of over 200 original papers, over 50 editorials or invited reviews, 20 book sections, one edited book and several abstracts at national and international meetings.


On-going projects

-      An integrated approach to identify the mechanism of resistance to copanlisib and venetoclax in marginal zone lymphoma

-      Transcriptome analysis to improve the outcome prediction and to identify novel therapeutics targets in follicular lymphoma patients

-      Genetic screening of enhancer RNAs to understand their causative biological role in refractory diffuse large B cell lymphoma

-      Development of a microfluidic platform for real-time detection of SARS-CoV-2 virus based on multifunctional silica membrane biosensors

-      Characterization of specific enhancer RNAs involved in ibrutinib resistance mechanism in marginal zone lymphoma

-      Ultra-conserved long non-coding RNAs in B-cell lymphoma

-      Finding a way to by-pass the resistance to PI3K inhibitors in marginal zone lymphomas 

-      An implantable device to tailor treatment in patients with lymphoma

-      CA18238 - European transdisciplinary networking platform for marine biotechnology

-      Targeted agents in splenic marginal zone lymphoma: mechanisms of resistance and new combinations

-      An international phase III multicenter, randomized study with lenalidomide maintenance versus observation after intensified induction regimen containing rituximab followed by high dose chemotherapy and autologous stem cell transplantation as first line treatment in adult patients with advanced mantle cell lymphoma: Identification of DNA and methylation changes associated with the clinical outcome

-      Development of novel anti-lymphoma agents